Symbiotec Pharmalab Limited (SYMBIOTEC) reports strong Q2 & H1FY27 performance with 11% Y-o-Y API revenue growth and key business updates.
Symbiotec Pharmalab Limited (SYMBIOTEC) reports steady performance for Q1FY27 with revenue up 6% and EBITDA growth of 9%.